{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T05:10:07Z","timestamp":1752210607508,"version":"3.41.2"},"reference-count":30,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.59556\/japi.72.0558","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:49:54Z","timestamp":1752209394000},"page":"15-19","source":"Crossref","is-referenced-by-count":0,"title":["Mycophenolate Mofetil with Steroid, a Reasonable Alternative to Current First-line Therapy, for Idiopathic Membranous Nephropathy in Resource-constrained Settings: A Randomized, Open-label Study"],"prefix":"10.59556","volume":"72","author":[{"given":"Manjuri","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prodip Kumar","family":"Doley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Pegu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(1):","key":"key20250711044947_B1","doi-asserted-by":"crossref","first-page":"69.","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy.","volume":"7","author":"Ronco","year":"2021;","journal-title":"Nat Rev Dis Primers"},{"issue":"(2):","key":"key20250711044947_B2","doi-asserted-by":"crossref","first-page":"102\u2013","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.","volume":"114","author":"Lai","year":"2015;","journal-title":"J Formos Med Assoc"},{"issue":"(1):","key":"key20250711044947_B3","doi-asserted-by":"crossref","first-page":"31\u2013","DOI":"10.1007\/s00467-013-2717-z","article-title":"Membranous nephropathy: not just a disease for adults.","volume":"30","author":"Ayalon","year":"2015;","journal-title":"Pediatr Nephrol"},{"issue":"(2):","key":"key20250711044947_B4","doi-asserted-by":"crossref","first-page":"9.","DOI":"10.7603\/s40681-014-0009-y","article-title":"Genetic susceptibility to idiopathic membranous nephropathy in high-prevalence area, Taiwan.","volume":"4","author":"Chen","year":"2014;","journal-title":"Biomedicine (Taipei)"},{"issue":"(12):","key":"key20250711044947_B5","doi-asserted-by":"crossref","first-page":"2145\u2013","DOI":"10.1093\/ndt\/gfy049","article-title":"Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model.","volume":"33","author":"Hamilton","year":"2018;","journal-title":"Nephrol Dial Transplant"},{"issue":"(1):","key":"key20250711044947_B6","doi-asserted-by":"crossref","first-page":"352.","DOI":"10.1186\/s12882-019-1539-z","article-title":"Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.","volume":"20","author":"Nikolopoulou","year":"2019;","journal-title":"BMC Nephrol"},{"issue":"(15):","key":"key20250711044947_B7","doi-asserted-by":"crossref","first-page":"946\u2013","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.","volume":"310","author":"Ponticelli","year":"1984;","journal-title":"N Engl J Med"},{"key":"key20250711044947_B8","doi-asserted-by":"crossref","first-page":"1600\u2013","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.","volume":"48:","author":"Ponticelli","year":"1995;","journal-title":"Kidney Int"},{"key":"key20250711044947_B9","doi-asserted-by":"crossref","first-page":"444\u2013","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.","volume":"9:","author":"Ponticelli","year":"1998;","journal-title":"J Am Soc Nephrol"},{"issue":"(6):","key":"key20250711044947_B10","doi-asserted-by":"crossref","first-page":"1899\u2013","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.","volume":"18","author":"Jha","year":"2007;","journal-title":"J Am Soc Nephrol"},{"key":"key20250711044947_B11","doi-asserted-by":"crossref","first-page":"268\u2013","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"95:","author":"Floege","year":"2019;","journal-title":"Kidney Int"},{"key":"key20250711044947_B12","doi-asserted-by":"crossref","first-page":"8\u2013","DOI":"10.4103\/jesnt.jesnt_37_18","article-title":"Analysis of different treatments and their outcomes in idiopathic membranous nephropathy: a single-center observational study.","volume":"19:","author":"Rao","year":"2019;","journal-title":"J Egypt Soc Nephrol Transplant"},{"issue":"(10):","key":"key20250711044947_B13","doi-asserted-by":"crossref","first-page":"2653\u2013","DOI":"10.1016\/j.ekir.2021.07.028","article-title":"Long-term follow-up of cyclical cyclophosphamide and steroids versus tacrolimus and steroids in primary membranous nephropathy.","volume":"6","author":"Ramachandran","year":"2021;","journal-title":"Kidney Int Rep"},{"issue":"(5):","key":"key20250711044947_B14","doi-asserted-by":"crossref","first-page":"787\u2013","DOI":"10.2215\/CJN.07570712","article-title":"Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.","volume":"8","author":"Chen","year":"2013;","journal-title":"Clin J Am Soc Nephrol"},{"issue":"(1):","key":"key20250711044947_B15","first-page":"12\u2013","article-title":"Study of hypothalamic pituitary adrenal axis in patients of membranous nephropathy receiving modified Ponticelli regimen.","volume":"25","author":"Ramachandran","year":"2015;","journal-title":"Indian J Nephrol"},{"issue":"(5):","key":"key20250711044947_B16","doi-asserted-by":"crossref","first-page":"629\u2013","DOI":"10.1093\/ckj\/sfz127","article-title":"Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.","volume":"12","author":"Rojas-Rivera","year":"2019;","journal-title":"Clin Kidney J"},{"issue":"(6):","key":"key20250711044947_B17","doi-asserted-by":"crossref","first-page":"576\u2013","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.","volume":"12","author":"Chan","year":"2007;","journal-title":"Nephrology (Carlton)"},{"issue":"(6):","key":"key20250711044947_B18","doi-asserted-by":"crossref","first-page":"1926\u2013","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.","volume":"23","author":"Senthil Nayagam","year":"2008;","journal-title":"Nephrol Dial Transplant"},{"key":"key20250711044947_B19","doi-asserted-by":"crossref","first-page":"4996239.","DOI":"10.1155\/2022\/4996239","article-title":"Treatment of idiopathic membranous nephropathy for moderate or severe proteinuria: a systematic review and network meta-analysis.","volume":"2022:","author":"Chen","year":"2022;","journal-title":"Int J Clin Pract"},{"issue":"(3):","key":"key20250711044947_B20","doi-asserted-by":"crossref","first-page":"1098\u2013","DOI":"10.1046\/j.1523-1755.2002.00214.x","article-title":"Mycophenolate mofetil treatment for primary glomerular diseases.","volume":"61","author":"Choi","year":"2002;","journal-title":"Kidney Int"},{"issue":"(3):","key":"key20250711044947_B21","doi-asserted-by":"crossref","first-page":"269\u2013","DOI":"10.1016\/j.nefroe.2019.05.003","article-title":"A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: a meta-analysis.","volume":"39","author":"Li","year":"2019;","journal-title":"Nefrologia (Engl Ed)"},{"issue":"(1):","key":"key20250711044947_B22","doi-asserted-by":"crossref","first-page":"840\u2013","DOI":"10.1080\/0886022X.2021.1914655","article-title":"Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials.","volume":"43","author":"Huang","year":"2021;","journal-title":"Ren Fail"},{"issue":"(9):","key":"key20250711044947_B23","doi-asserted-by":"crossref","first-page":"2729\u2013","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy.","volume":"28","author":"van den Brand","year":"2017;","journal-title":"J Am Soc Nephrol"},{"issue":"(16):","key":"key20250711044947_B24","doi-asserted-by":"crossref","first-page":"e19804.","DOI":"10.1097\/MD.0000000000019804","article-title":"Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis.","volume":"99","author":"Lu","year":"2020;","journal-title":"Medicine (Baltimore)"},{"issue":"(4):","key":"key20250711044947_B25","doi-asserted-by":"crossref","first-page":"972\u2013","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial.","volume":"32","author":"Scolari","year":"2021;","journal-title":"J Am Soc Nephrol"},{"issue":"(6):","key":"key20250711044947_B26","doi-asserted-by":"crossref","first-page":"1012\u2013","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.","volume":"46","author":"du Buf-Vereijken","year":"2005;","journal-title":"Am J Kidney Dis"},{"key":"key20250711044947_B27","doi-asserted-by":"crossref","first-page":"1156\u2013","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.","volume":"343:","author":"Chan","year":"2000;","journal-title":"N Engl J Med"},{"key":"key20250711044947_B28","doi-asserted-by":"crossref","first-page":"1076\u2013","DOI":"10.1681\/ASN.2004080686","article-title":"Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis.","volume":"16:","author":"Chan","year":"2005;","journal-title":"J Am Soc Nephrol"},{"key":"key20250711044947_B29","unstructured":"IndiaMART. Available from https:\/\/dir.indiamart.com\/impcat\/mycophenolate-mofetil-tablets.html. [Last accessed November, 2022]."},{"key":"key20250711044947_B30","unstructured":"IndiaMART. Available from https:\/\/dir.indiamart.com\/impcat\/rituxan.html [Last accessed November, 2022]."}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:49:57Z","timestamp":1752209397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-6-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.59556\/japi.72.0558"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0558","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}